

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

Claim 1 (Previously presented): A replication-competent adenovirus vector comprising a first adenovirus gene essential for replication under transcriptional control of an Epstein Ban-Virus (EBV)-specific transcriptional regulatory element (TRE) comprising a sequence selected from the group consisting of a sequence upstream of the translational start codon for the LMP1 gene presented as SEQ ID NO:1, a sequence upstream of the translational start codon for the LMP2A gene presented as SEQ ID NO:2 and the Cp promoter sequence presented as SEQ ID NO:3.

**Claim 2 (Canceled)**

Claim 3 (Previously presented): The adenovirus vector according to Claim 1, wherein said EBV-specific TRE comprises the LMP1 sequence set forth in SEQ ID NO:1.

Claim 4 (Previously presented): The adenovirus vector according to Claim 3, wherein said EBV-specific TRE comprises an ED-L1 regulatory region presented as nucleotides 64 to 70.of SEQ ID NO:1.

**Claims 5-6 (Canceled)**

Claim 7 (Currently amended): The adenovirus vector according to Claim 1-6,  
wherein said EBV-specific TRE comprises the LMP2A EBV sequence set forth in SEQ ID  
NO:2.

Claim 8 (Previously presented): The adenovirus vector according to Claim 1,  
wherein said, EBV-specific TRE comprises the Cp promoter set forth in SEQ ID NO:3.

Claim 9 (Previously presented): The adenovirus vector according to Claim 8,  
wherein said EBV-specific TRE further comprises the FR enhancer set forth in SEQ ID NO:4.

Claim 10 (Previously presented): The adenovirus vector according to Claim 1,  
wherein said EBV-specific TRE further comprises the FR enhancer set forth in SEQ ID NO:4.

Claim 11 (Canceled)

Claim 12 (Previously presented): The adenovirus vector according to Claim 1,  
further comprising a second adenoviral gene co-transcribed under transcriptional control of said  
EBV-specific TRE.

Claim 13 (original): The adenovirus vector according to Claim 12, wherein the  
second adenoviral gene is under translational control of an IRES.

Claim 14 (Previously presented): The adenovirus vector of Claim 1, wherein  
said first adenoviral gene essential for replication is E1A or E1B.

Claim 15 (original): The adenovirus vector of Claim 14, wherein E1A or E1B has a mutation in, or deletion of, its endogenous promoter.

Claim 16 (original): The adenovirus vector of Claim 15, wherein E1 B has a deletion of the 19-kDa region.

Claim 17 (original): A composition comprising:  
a replication-competent adenovirus vector according to Claim 1 and a pharmaceutically acceptable excipient.

Claim 18 (Previously presented): An isolated host cell comprising the adenovirus vector of claim 1.

Claim 19 (Previously presented): A composition comprising:  
a replication-competent adenovirus vector according to Claim 10 and a pharmaceutically acceptable excipient.

Claim 20 (Previously presented): An isolated host cell comprising the adenovirus vector of Claim 10.